Invited Lecture 1.4
Title : Hybrid Brachytherapy followed-by IMRT (HyBIRT) for oral tongue cancer definitive treatment
Date: 11th October 2024
Time: 02:45pm – 03:00pm
Venue : Ballroom 1 (Level 10)
Chairs:
- Hafiz Zin
Speaker: Assoc. Prof. Dr. Gokula Kumar Appalanaido (Malaysia)
Abstract
Combination of upfront high dose rate interstitial brachytherapy (HDRIBT) followed-by concurrent chemo-IMRT has shown good local control in oral tongue squamous cell carcinoma. However, combining both these treatment modality involve complex radiotherapy treatment planning process. A process that starts with HDRIBT applicator implantation and treatment planning with subsequent IMRT in mind, co-registration of the HDRIBT plan with the IMRT plan and ends with delivering the IMRT dose while observing the toxicity. Low dose HDRIBT of 20Gy in 5F is followed-by full IMRT dose of 69.96Gy in 33F to gross tumor volume (GTV) at the nodes is delivered. Pre-brachytherapy 25Gy isodose volume is constrained to 63Gy Dmax while 59.5Gy is prescribed. This dose painting method is applied to other dose level in the neck based on the risk levels. This radiotherapy technique that we named as HyBIRT (Hybrid Brachytherapy followed-by IMRT) is a complex technique that involve tedious planning methods by very experienced physicist. The clinical results of this technique was presented as a proffered paper in the ESTRO 2023 and ESTRO 2024 annual scientific meetings.
​​